Computational Psychiatry and the Placebo Effect in Psychosis
Biological Psychiatry Global Open Science · 2023-10 · 3 (4) · 585-586
DOI: 10.1016/j.bpsgos.2023.08.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biological Psychiatry Global Open Science, 2023-10. Verfasst von Lauren Y Atlas. Beteiligte Einrichtung: National Center for Complementary and Integrative Health, National Institutes of Health, Baltimore, Maryland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Intramural NIH HHS, National Center for Complementary and Integrative Health.
Abstract (Originalsprache)
Placebo effects in psychiatry are robust and are growing over time. Placebo researchers differentiate between placebo responses, which are any bene fi cial outcomes in response to inert treatments (including natural history and regression to the mean), and placebo effects, which depend on expectations, learning, and psychological factors attributable to the psychosocial context surrounding treatment (1). While clinical trials recognize and control for placebo responses by comparing active and inert treatments, isolating placebo effects on clinical outcomes requires a no-history control group (e.g., a waiting list control group). Meta-analyses of clinical outcomes indicate that placebo effects are largest in pain and subjective outcomes (2), which are central in most psychiatric conditions. As placebo effects on subjective outcomes are challenging to differentiate from response bias, a great deal of research has focused on isolating the neurobiological mechanisms of the placebo effect to determine whether placebo effects re fl ect response bias or true changes in disease-relevant biological processes. Most studies of placebo mechanisms have focused on placebo analgesia (i.e., reductions in pain), as well as a few studies of depression and anxiety [for review, see (3)]. However, few have considered the role of placebo effects in psychosis. In the current issue of Biological Psychiatry: Global Open Science , Hird et al. (4) present a call to action for researchers to consider and study the placebo effect in psychosis. They review meta-analyses of randomized controlled trials for anti-psychotic medications that indicate signi fi cant placebo responses on symptoms and rating scales and suggest that placebo responses increase over time. Notably, none of the studies include a natural history control group, and thus we cannot distinguish between placebo responses and placebo effects. To determine whether these bene fi ts re fl ect placebo effects per se rather than nonspeci fi c effects, such as regression to the mean, future clinical trials of antipsychotics should include waiting list control groups or other natural history comparison groups when possible. In addition, the reviewed
Autor:innen und Institutionen
- National Center for Complementary and Integrative Health, National Institutes of Health, Baltimore, Maryland.
- National Institute of Mental Health, National Institutes of Health, Baltimore, Maryland.
- National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland.
Förderung
- Intramural NIH HHS
- National Center for Complementary and Integrative Health
Zitieren
APA
Atlas, L. Y. (2023). Computational Psychiatry and the Placebo Effect in Psychosis. Biological Psychiatry Global Open Science, 3(4), 585-586. https://doi.org/10.1016/j.bpsgos.2023.08.006
Vancouver
Atlas LY. Computational Psychiatry and the Placebo Effect in Psychosis. Biological Psychiatry Global Open Science. 2023;3(4):585-586. doi:10.1016/j.bpsgos.2023.08.006
BibTeX
@article{Atlas2023,
author = {Atlas, Lauren Y},
title = {Computational Psychiatry and the Placebo Effect in Psychosis},
journal = {Biological Psychiatry Global Open Science},
year = {2023},
volume = {3},
number = {4},
pages = {585--586},
doi = {10.1016/j.bpsgos.2023.08.006}
}
EUVIMED